MSB 7.69% $1.19 mesoblast limited

Ann: CEO Presentation to 2023 Annual General Meeting, page-33

  1. 16,651 Posts.
    lightbulb Created with Sketch. 2375
    I'm expecting
    1. A capital raise in short order

    2. An expression of surprise, bewilderment and befuddlement from SI when the FDA says no approval for aGVHD without a successful result from a properly controlled randomised clinical trial in adults.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.